Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585753 | 0.84 | HTR1A (0.43) | HTR1ASLC6A2EPHX2HTR2C | |
| SCHEMBL2639856 | 0.83 | HTR1A (0.46) | HTR1ASLC6A2EPHX2 | |
| SCHEMBL2640018 | 0.82 | SLC6A2 (0.46) | HTR1ASLC6A2EPHX2HTR2C | |
| SCHEMBL4314317 | 0.81 | NISCH (0.44) | HTR1ASLC6A2HTR2C | |
| SCHEMBL4313464 | 0.81 | HTR1A (0.46) | HTR1ASLC6A2EPHX2HTR2C | |
| SCHEMBL2639820 | 0.79 | EPHX2 (0.44) | HTR1ASLC6A2EPHX2HTR2C | |
| SCHEMBL2639783 | 0.79 | HTR1A (0.49) | HTR1ASLC6A2EPHX2HTR2C | |
| SCHEMBL2640109 | 0.78 | HTR1A (0.44) | HTR1ASLC6A2EPHX2HTR2C | |
| SCHEMBL4314845 | 0.78 | HTR2C (0.47) | HTR1ASLC6A2HTR2C | |
| SCHEMBL4312809 | 0.78 | CYP2C19 (0.49) | HTR1ASLC6A2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR1A 15/4885SLC6A2 36/4885EPHX2 385/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR1A 15/4885SLC6A2 36/4885EPHX2 385/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR1A 15/4885SLC6A2 36/4885EPHX2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.